Charles River Laboratories
466 hedge funds and large institutions have $8.14B invested in Charles River Laboratories in 2020 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 153 increasing their positions, 165 reducing their positions, and 37 closing their positions.
141% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 37
38% more capital invested
Capital invested by funds: $5.91B → $8.14B (+$2.23B)
26% more call options, than puts
Call options by funds: $73M | Put options by funds: $57.7M
12% more funds holding
Funds holding: 416 → 466 (+50)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
0.37% less ownership
Funds ownership: 94.76% → 94.38% (-0.37%)
7% less repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 165
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$140M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$47.8M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$43M |
| 4 |
THP
Tower House Partners
London,
United Kingdom
|
+$36.7M |
| 5 |
LCM
Lakewood Capital Management
New York
|
+$35.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$101M |
| 2 |
HM
HealthCor Management
New York
|
-$77.2M |
| 3 |
Renaissance Technologies
New York
|
-$48.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$37.5M |
| 5 |
CCM
Channing Capital Management
Chicago,
Illinois
|
-$36.7M |
CRL Hedge Fund Activity: Q2 2020 in Review
466 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2020, worth a combined $8.14B — up 38% from $5.91B a quarter earlier.
Buyers outnumbered sellers: 89 funds opened new CRL positions and 37 closed out — a net gain of 52 holders — while 153 added to existing stakes and 165 trimmed.
The largest buyer was BlackRock, adding an estimated $140M. The largest seller was AQR Capital Management, cutting an estimated $101M.
- 466 institutional investors held Charles River Laboratories (CRL) as of Q2 2020, up from 416 in Q1 2020.
- Funds reported $8.14B of Charles River Laboratories stock for Q2 2020, up 38% quarter-over-quarter.
- 89 funds opened new Charles River Laboratories positions in Q2 2020 and 37 closed out, a net change of +52 holders.
- The largest Charles River Laboratories buyer in Q2 2020 was BlackRock, an estimated $140M added.
- The largest Charles River Laboratories seller in Q2 2020 was AQR Capital Management, an estimated $101M sold.
Based on aggregated 13F filings for Q2 2020.